Vaxart, Inc. Files 8-K: Other Events & Exhibits
Ticker: VXRT · Form: 8-K · Filed: Apr 30, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, biotech
Related Tickers: VXRT
TL;DR
Vaxart filed an 8-K on 4/30, reporting 'other events' and financials. No specific details yet.
AI Summary
Vaxart, Inc. filed an 8-K on April 30, 2024, reporting other events and financial statements. The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is incorporated in Delaware and its fiscal year ends on December 31st. The filing does not contain specific financial figures or details about the 'other events' reported.
Why It Matters
This 8-K filing indicates Vaxart has reported material events and financial information to the SEC, which could include updates on its drug development pipeline or corporate matters.
Risk Assessment
Risk Level: medium — 8-K filings can contain significant corporate or financial updates, but without specific details in this filing, the risk level is moderate.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
- April 30, 2024 (date) — Date of Report
FAQ
What specific 'Other Events' are being reported by Vaxart, Inc. in this 8-K filing?
The provided text of the 8-K filing indicates that 'Other Events' are being reported, but it does not specify the nature of these events.
When was Vaxart, Inc. previously known by other names?
Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc. (name change date 20160413), Biota Pharmaceuticals, Inc. (name change date 20121113), and NABI BIOPHARMACEUTICALS (name change date 20100719).
What is the Commission File Number for Vaxart, Inc.?
The Commission File Number for Vaxart, Inc. is 001-35285.
In which state is Vaxart, Inc. incorporated?
Vaxart, Inc. is incorporated in Delaware.
What is the business address and phone number for Vaxart, Inc.?
The business address for Vaxart, Inc. is 170 Harbor Way, Suite 300, South San Francisco, CA 94080, and the business phone number is (650) 550-3500.
Filing Stats: 444 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-04-30 16:22:06
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
Filing Documents
- vxrt20240430_8k.htm (8-K) — 28KB
- ex_664492.htm (EX-99.1) — 17KB
- 0001437749-24-013983.txt ( ) — 180KB
- vxrt-20240430.xsd (EX-101.SCH) — 3KB
- vxrt-20240430_def.xml (EX-101.DEF) — 11KB
- vxrt-20240430_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240430_pre.xml (EX-101.PRE) — 11KB
- vxrt20240430_8k_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On April 30, 2024, Vaxart, Inc. issued a press release announcing it has completed the topline analysis for the Phase 1 clinical trial evaluating Vaxart, Inc.'s oral pill bivalent norovirus vaccine candidate. A copy of the press release is filed as Exhibit 99.1 hereto and, other than the quotes by Dr. James F. Cummings, is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated April 30, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vaxart, Inc. Dated: April 30, 2024 By: /s/ STEVEN LO Steven Lo President and Chief Executive Officer